MX2017006205A - Tratamiento de la intoleracia a la alimentacion enteral. - Google Patents

Tratamiento de la intoleracia a la alimentacion enteral.

Info

Publication number
MX2017006205A
MX2017006205A MX2017006205A MX2017006205A MX2017006205A MX 2017006205 A MX2017006205 A MX 2017006205A MX 2017006205 A MX2017006205 A MX 2017006205A MX 2017006205 A MX2017006205 A MX 2017006205A MX 2017006205 A MX2017006205 A MX 2017006205A
Authority
MX
Mexico
Prior art keywords
enteral feeding
treatment
feeding intolerance
intolerance
ulimorelin
Prior art date
Application number
MX2017006205A
Other languages
English (en)
Inventor
Wurtman David
James Joyce
scott harris M
Original Assignee
Lyric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyric Pharmaceuticals Inc filed Critical Lyric Pharmaceuticals Inc
Publication of MX2017006205A publication Critical patent/MX2017006205A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La intolerancia a la alimentación enteral (EFI, por sus siglas en inglés) se puede tratar de forma eficaz mediante la administración de dosis terapéuticamente efectivas de ulimorelina cada 8 horas (tres veces por día). Se puede obtener beneficio terapéutico a partir de dosificación diaria consecutiva, incluyendo durante periodos de hasta una semana o más tiempo.
MX2017006205A 2014-11-12 2015-11-11 Tratamiento de la intoleracia a la alimentacion enteral. MX2017006205A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462078888P 2014-11-12 2014-11-12
PCT/US2015/060222 WO2016077498A1 (en) 2014-11-12 2015-11-11 Treatment of enteral feeding intolerance

Publications (1)

Publication Number Publication Date
MX2017006205A true MX2017006205A (es) 2017-11-17

Family

ID=55955006

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006205A MX2017006205A (es) 2014-11-12 2015-11-11 Tratamiento de la intoleracia a la alimentacion enteral.

Country Status (12)

Country Link
US (1) US10092621B2 (es)
EP (1) EP3217996A4 (es)
JP (1) JP2017533951A (es)
KR (1) KR20170085539A (es)
CN (1) CN107106636A (es)
AU (1) AU2015346323A1 (es)
CA (1) CA2967355A1 (es)
EA (1) EA201791038A1 (es)
IL (1) IL252234A0 (es)
MX (1) MX2017006205A (es)
SG (1) SG11201703884PA (es)
WO (1) WO2016077498A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015346323A1 (en) 2014-11-12 2017-06-22 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance
WO2017197131A1 (en) * 2016-05-11 2017-11-16 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and muscle wasting

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US20090259279A1 (en) 2002-03-22 2009-10-15 Dobak Iii John D Splanchnic nerve stimulation for treatment of obesity
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2009531385A (ja) 2006-03-31 2009-09-03 グラクソ グループ リミテッド 成長ホルモン分泌促進物質（ｇｈｓ）受容体アゴニストとしてのピペラジン誘導体
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
BR112012007183A2 (pt) 2009-09-30 2017-06-20 Tranzyme Pharma Inc solvato de um sal de um composto macrocíclico, forma polimórfica, processos para preparar a forma polimórfica e uma composição farmacêutica, composição farmacêutica, sal de um composto macrocíclico, e, métodos para estimular motilidade gastrintestinal, para tratar um distúrbio gastrintestinal e para tratar um indivíduo, e, kit
US20110105389A1 (en) 2009-10-30 2011-05-05 Hoveyda Hamid R Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
US20130261011A1 (en) 2012-03-30 2013-10-03 Tufts Medical Center, Inc. Analyzing neonatal saliva and readiness to feed
US20130316002A1 (en) 2012-05-22 2013-11-28 Depomed, Inc. Compositions and methods for treating gastrointestinal motility dysfunction
EP2854810A4 (en) 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
KR20150070180A (ko) 2012-10-24 2015-06-24 다이이찌 산쿄 가부시키가이샤 근위축성 측삭 경화증 치료제
AU2015346323A1 (en) 2014-11-12 2017-06-22 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance
WO2017083882A1 (en) 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
WO2017097328A1 (en) 2015-12-07 2017-06-15 Arcelik Anonim Sirketi Divider assembly for use in the vegetable drawer of a refrigerator
WO2017197131A1 (en) 2016-05-11 2017-11-16 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and muscle wasting
WO2017197328A1 (en) 2016-05-12 2017-11-16 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and muscle wasting with relamorelin

Also Published As

Publication number Publication date
KR20170085539A (ko) 2017-07-24
SG11201703884PA (en) 2017-06-29
IL252234A0 (en) 2017-07-31
US20170304395A1 (en) 2017-10-26
JP2017533951A (ja) 2017-11-16
AU2015346323A1 (en) 2017-06-22
US10092621B2 (en) 2018-10-09
WO2016077498A1 (en) 2016-05-19
CN107106636A (zh) 2017-08-29
CA2967355A1 (en) 2016-05-19
EP3217996A4 (en) 2018-06-20
EA201791038A1 (ru) 2017-11-30
EP3217996A1 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
PH12018500981A1 (en) Treatment of osteoarthritis
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ730809A (en) Methods for treating filoviridae virus infections
MX2017004471A (es) Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
NZ760790A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
MX2017008386A (es) Administración específica del sitio de un inhibidor de btk.
MX2018012719A (es) Ram negativas para tratar la dermatitis atopica.
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
NZ751137A (en) System, device and methods of seed treatment
PH12016502352A1 (en) Pharmaceutical composition
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
MX2017006205A (es) Tratamiento de la intoleracia a la alimentacion enteral.
TW201613606A (en) Therapeutic drug for chronic renal failure
PH12018500946A1 (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
UA95834U (uk) Спосіб лікування гострого ішемічного інсульту
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA99228U (uk) Спосіб медикаментозного лікування хворих на стабільну стенокардію та субклінічний гіпотиреоз
MX2014013240A (es) Composicion farmaceutica para el tratamiento de la disfuncion erectil a base de un farmaco inhibidor de la enzima pde-5 (fosfodiesterasa tipo 5) en tabletas.